Literature DB >> 22331238

An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers.

Wendelin K Nelson1, Richard N Formica, Dennis L Cooper, Peter E Schwartz, Thomas J Rutherford.   

Abstract

STUDY
OBJECTIVE: Different equations used to estimate creatinine clearance (Cl(cr)) in obese oncology patients can produce divergent estimated creatinine clearance values, which in turn can result in significantly different calculated carboplatin doses. Standardization of the calculation of creatinine clearance in patients of all body types is a desirable goal. The objective of our study was to examine the impact of increasing body mass index on the accuracy of creatinine clearance estimation methods and to determine the optimal equation for creatinine clearance estimation in the obese adult female cancer patient.
DESIGN: Retrospective data analysis. PATIENTS: We compared the estimated creatinine clearance values produced by each of 11 equations to 24-hour creatinine clearance values measured in 119 adult female patients with gynecologic cancers grouped according to body composition.
MEASUREMENTS AND MAIN RESULTS: We applied simple linear regression and Tukey mean-difference analysis to assess the relationship between estimated creatinine clearance values produced by these equations and measured creatinine clearance values for each patient. The relationship between measured creatinine clearance and estimated creatinine clearance produced by all equations displayed lower linear regression R (2) values and higher limits of agreement in obese patients than in nonobese groups. Agreement between measured and estimated creatinine clearance produced by the Cockcroft-Gault equation is sensitive to the particular weight parameter incorporated and is lowest using ideal weight or actual body weight. The Cockcroft-Gault equation incorporating an intermediate weight value reduced estimation bias. The Jelliffe equation produced the lowest R (2) values.
CONCLUSION: Available model equations are less reliable for predicting creatinine clearance in obese female cancer patients (body mass index >30) than in nonobese patients. A measured glomerular filtration rate or creatinine clearance value is most accurate in obese female cancer patients. When using Cockcroft-Gault equation for estimation in this patient population, however, an intermediate weight value (adjusted or modified-adjusted) rather than ideal or actual body weight should be used.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22331238     DOI: 10.1177/1078155211435714

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  5 in total

1.  Association between renal function and chemotherapy-related toxicity in older adults with cancer.

Authors:  Lindsay L Peterson; Arti Hurria; Tao Feng; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Ilya Glezerman; Vani Katheria; Laura Zavala; David D Smith; Can-Lan Sun; William P Tew
Journal:  J Geriatr Oncol       Date:  2016-11-14       Impact factor: 3.599

2.  Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance.

Authors:  Melanie White-Koning; Marie Noëlle Paludetto; Félicien Le Louedec; Laurence Gladieff; Christine Chevreau; Etienne Chatelut; Florent Puisset
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-09       Impact factor: 3.333

Review 3.  Methods of Estimating Kidney Function for Drug Dosing in Special Populations.

Authors:  Laura A Hart; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

Review 4.  Modern pharmacological treatment of obese patients.

Authors:  Marcus May; Christoph Schindler; Stefan Engeli
Journal:  Ther Adv Endocrinol Metab       Date:  2020-01-22       Impact factor: 3.565

5.  A novel nomogram to predict the reliability of estimated glomerular filtration rate formulae in oncology patients.

Authors:  Yichun Cheng; Liu Huang; Yunfeng Han; Chummun Vanisha; Shuwang Ge; Gang Xu
Journal:  BMC Cancer       Date:  2020-06-08       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.